Neal Shore, MD, FACS, discussed findings from the SunRISe-4 trial of TAR-200 and cetrelimab in muscle-invasive bladder cancer ...

A phase 3 trial of Johnson & Johnson's TAR-200 therapy in bladder cancer has failed to show efficacy, although the company is still confident in the potential of the programme. The SunRISe-2 study ...

Johnson & Johnson has kicked off a marketing application in the US for TAR-200 as a treatment for a form of bladder cancer, using a novel technology that releases the drug intravesically ...

There is a high unmet need for effective neoadjuvant treatments for muscle-invasive bladder cancer for patients who cannot tolerate or refuse cisplatin chemotherapy.

J&J is developing its asset and CG Oncology is developing cretostimogene for non-muscle invasive bladder cancer. TAR-200 is designed to provide targeted local release of gemcitabine into the ...